Clinical Trials
36 trialsEflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Milton S. Hershey Medical Center
DFMO
Montefiore Medical Center
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
PEDS-PLAN
Milton S. Hershey Medical Center
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Milton S. Hershey Medical Center
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Milton S. Hershey Medical Center
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
PACES
SWOG Cancer Research Network
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
NMTT
Milton S. Hershey Medical Center
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
University of Alabama at Birmingham
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
Mayo Clinic
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
DFMO
New Approaches to Neuroblastoma Therapy Consortium
Chemoprevention of Gastric Carcinogenesis
Vanderbilt-Ingram Cancer Center
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Milton S. Hershey Medical Center
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
Milton S. Hershey Medical Center
STELLAR
Orbus Therapeutics, Inc.
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients
University of Wisconsin, Madison
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
University of Wisconsin, Madison
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
National Cancer Institute (NCI)
Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
M.D. Anderson Cancer Center
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
University of California, Irvine
Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
University of Arizona
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
National Cancer Institute (NCI)
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
Cancer Prevention Pharmaceuticals, Inc.
Eflornithine in Treating Patients With Bladder Cancer
National Cancer Institute (NCI)
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
University of Alabama at Birmingham
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
University of Michigan Rogel Cancer Center